LLY vs. SPCX: Eli Lilly vs. Space Exploration Stock Comparison

Company Profile

Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Space Exploration (SPCX) belongs to Communication Services (Telecommunication Services) — their GICS classifications point to very different parts of the market.

Eli Lilly (LLY) has been public since June 1, 1972, giving it decades of market history across multiple cycles, while Space Exploration (SPCX) listed only on June 12, 2026 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Space Exploration (SPCX) has a highly aggressive beta of 16.03, indicating much higher sensitivity to broad-market moves, while Eli Lilly (LLY) is defensive at 0.50 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Both LLY and SPCX need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Eli Lilly (LLY) earns 102.29% on shareholders’ equity, ranked against its industry; Space Exploration (SPCX) has no ROE this period.

Space Exploration (SPCX) reports a negative net margin of -35.66%, usually indicating a net loss over the period. Meanwhile Eli Lilly (LLY) reports 33.53%, ranking against industry peers normally.

Space Exploration (SPCX) reports a negative operating margin of -1.80%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Eli Lilly (LLY) reports 54.22%, ranking against industry peers normally.

Profitability Metrics

Growth

Space Exploration (SPCX) at 33.24% clears its industry range for revenue growth, far stronger top-line momentum than Eli Lilly (LLY) at 44.70%, which is closer to a typical peer reading.

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Space Exploration (SPCX) at -25,600.00% falls below its industry range — a large difference in per-share earnings trajectories.

Growth Metrics

Financial Strength

Space Exploration (SPCX) at 5.12 carries current ratio above its industry’s typical mid-range, while Eli Lilly (LLY) at 1.36 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Space Exploration (SPCX) at 0.31 keeps leverage in the lower quartile, while Eli Lilly (LLY) at 1.62 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Space Exploration (SPCX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.54%, ranking against industry peers normally.

Space Exploration (SPCX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.69%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Eli Lilly (LLY) trades at 40.00 times trailing earnings, ranked against its peers, while Space Exploration (SPCX) has no P/E ratio this period.

Eli Lilly (LLY) at 13.27 prices around its industry’s typical P/S ratio, while Space Exploration (SPCX) at 76.14 clears its benchmark range — SPCX looks notably rich on sales.

Measured against book value, both Eli Lilly (LLY) at 33.96 and Space Exploration (SPCX) at 13.79 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics